Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 5/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23901530 | 0.94 | AVPR2 (0.43) | AVPR2MGLLUSP30SPRP2RX7 | |
| SCHEMBL23901480 | 0.90 | AVPR2 (0.42) | AVPR2MGLLUSP30SPRP2RX7 | |
| SCHEMBL23901481 | 0.90 | AVPR2 (0.42) | AVPR2MGLLUSP30SPRP2RX7 | |
| SCHEMBL25453338 | 0.86 | AVPR2 (0.55) | AVPR2MGLLUSP30HPGDSMN1; SMN2 | |
| SCHEMBL25453329 | 0.84 | AVPR2 (0.50) | AVPR2MGLLUSP30HPGDSMN1; SMN2 | |
| SCHEMBL25453375 | 0.84 | AVPR2 (0.50) | AVPR2MGLLUSP30HPGDSMN1; SMN2 | |
| SCHEMBL23901527 | 0.83 | AVPR2 (0.40) | AVPR2MGLLUSP30SPRP2RX7 | |
| SCHEMBL23901568 | 0.83 | AVPR2 (0.40) | AVPR2MGLLUSP30SPRP2RX7 | |
| SCHEMBL25453331 | 0.81 | USP30 (0.45) | AVPR2MGLLUSP30HPGDSMN1; SMN2 | |
| SCHEMBL23901483 | 0.80 | USP30 (0.45) | USP30HPGDSPRP2RX7SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| WO-2021202600-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | AVPR2 4576/4885MGLL 2888/4885USP30 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.